GlassScriptPhysician profile
Ali A Bukhari
NPI 1760724017
$5,391.77
in general payments reported to CMS, 2019-2025
59 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $24.46 · 2021: $274 · 2022: $369 · 2023: $84.81 · 2024: $1,468 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,982 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,982.46 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $624.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $337.82 | 2024-2025 | |
| Pfizer INC. | $309.89 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $248.53 | 2022-2024 | Opdivo, Augtyro, Krazati |
| Daiichi Sankyo INC. | $227.91 | 2024-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $212.71 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Glaxosmithkline, LLC. | $204.74 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Abbvie INC. | $195.31 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $159.38 | 2022-2025 | Lynparza, Calquence, Enhertu |
| Jazz Pharmaceuticals INC. | $149.59 | 2019-2025 | |
| Genentech USA, INC. | $148.87 | 2024-2025 | Polivy, Venclexta, Itovebi |
| Pharmacyclics LLC, An Abbvie Company | $147.84 | 2019-2021 | |
| Incyte Corporation | $140.06 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $107.56 | 2019-2025 | Reblozyl |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $95.36 | 2025 | Tevimbra, Brukinsa |
| Eisai INC. | $91.99 | 2022-2025 | |
| Genzyme Corporation | $88.39 | 2024-2025 | |
| Gilead Sciences, INC. | $86.99 | 2024-2025 | Trodelvy |
| Array Biopharma INC | $85.01 | 2025 | Braftovi, Lorbrena, Mektovi |
| Merck Sharp & Dohme LLC | $84.25 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $83.52 | 2024-2025 | Verzenio, Jaypirca |
| Astellas Pharma US INC | $75.62 | 2024-2025 | Padcev, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $74.37 | 2024-2025 | Alunbrig, Iclusig |
| Aveo Pharmaceuticals, INC. | $69.58 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $67.61 | 2024-2025 | Danziten, Vivimusta |
| Tersera Therapeutics LLC | $67.10 | 2024-2025 | Zoladex, Quzyttir |
| Pharmaessentia USA Corporation | $65.36 | 2024-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $59.57 | 2024-2025 | Libtayo, Lynozyfic |
| Legend Biotech USA INC. | $57.50 | 2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $53.05 | 2023-2025 | Clonoseq |
| Caris Mpi, INC. | $46.68 | 2025 | Mi Cancer Seek |
| Sobi, INC | $43.03 | 2024-2025 | |
| Puma Biotechnology, INC. | $42.32 | 2025 | |
| Sumitomo Pharma America, INC. | $39.05 | 2025 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $37.94 | 2025 | Romvimza, Qinlock |
| Invivyd INC | $35.07 | 2024 | Pemgarda |
| Foundation Medicine, INC. | $33.77 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $31.12 | 2025 | Stimufend |
| Exelixis INC. | $30.12 | 2025 | Cabometyx |
| Emd Serono, INC. | $29.41 | 2024 | |
| Acrotech Biopharma INC. | $28.06 | 2024-2025 | Beleodaq |
| Pharmaand Gmbh | $27.91 | 2025 | Rubraca |
| Tolmar, INC. | $27.91 | 2025 | Eligard, Rubraca |
| Rigel Pharmaceuticals, INC. | $27.41 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Kyowa Kirin, INC. | $26.78 | 2025 | |
| Geron Corporation | $26.58 | 2025 | Rytelo |
| Lundbeck LLC | $25.85 | 2025 | Vyepti |
| Ipsen Biopharmaceuticals, INC | $25.60 | 2024 | Onivyde |
| Beigene USA, INC. | $25.12 | 2024 | Tevimbra |
| Telix Pharmaceuticals | $22.50 | 2025 | |
| Spectrum Pharmaceuticals INC. | $21.74 | 2024 | Rolvedon |
| Blueprint Medicines Corporation | $20.81 | 2024 | Ayvakit |
| Pharmacosmos Therapeutics INC. | $20.49 | 2024 | Monoferric |
| Coherus Oncology, INC. | $20.33 | 2023 | |
| Adc Therapeutics America, INC. | $19.74 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.83 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.29 | 2025 | Givlaari |
| Servier Pharmaceuticals LLC | $16.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Bukhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.